(See all James M. Burns' publications in PubMed.)
"Remarkable stability in patterns of blood-stage gene expression during episodes of non-lethal Plasmodium yoelii malaria"
Cernetich-Ott A, Daly TM, Vaidya AB, Bergman LW, and JM Burns, Jr.
Malaria J., in press. 2012.
"Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8"
Alaro JR, Angov E, Lopez AM, Zhou H, Long CA, and JM Burns, Jr.
Infect. Immun., 80: 2473-2484, 2012.
Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
Alaro JA, Lynch MM and JM Burns Jr.
Vaccine, 28: 6876-6884, 2010.
Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor reduce the severity of blood-stage malaria.
Thorat, S, Daly TM, Bergman LW, and JM Burns Jr.
Infection and Immunity, 78: 5151-5162, 2010.
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch, MM, Cernetich-Ott A, Weidanz WP and JM Burns Jr.
Clinical and Vaccine Immunology, 16:293-302, 2009.
Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-γ-dependent responses induced by vaccination and/or challenge infection.
Petritus PM and JM Burns Jr.
The Journal of Immunology, 180: 444, 2008.
Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q, Lynch MM, Romero M, and JM Burns Jr.
Infection and Immunity, 75: 1349, 2007.
Expression, localization and erythrocyte binding activity of Plasmodium yoelii merozoite surface protein-8.
Shi Q, Cernetich-Ott A, Lynch MM, and JM Burns Jr.
Molecular and Biochemical Parasitology, 149: 231, 2006.
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites.
Shi Q, Cernetich A, Daly TM, Galvan G, Vaidya AB, Bergman LW, and JM Burns Jr.
Infection and Immunity, 73: 6363, 2005.
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen-1 and merozoite surface protein-1 does not require IFN-γ or IL-4.
Burns Jr., JM, Flaherty JM, Nanavati P, and WP Weidanz.
Infection and Immunity, 72: 5605, 2004.
Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.
Burns Jr., JM, Flaherty PR, and WP Weidanz.
Vaccine, 21: 1843, 2003.
A protective GPI-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.
Burns Jr., JM, Belk CC, and PD Dunn.
Infection and Immunity, Vol. 68, No. 11, November 2000.
Infection and I An unusual tryptophan-rich domain characterizes two secreted antigens of Plasmodium yoelii infected erythrocytes.
Burns Jr., JM, Adeeku EK, Belk CC, and PD Dunn
Molecular and Biochemical Parasitology, 110: 11, 2000.
Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens.
Burns Jr., JM, Dunn PD, and DM Russo.
Infection and Immunity, 65: 3138, 1997.
Protective immunization with a novel membrane protein of Plasmodium yoelii - infected erythrocytes.
Burns Jr., JM, Adeeku EK, and PD Dunn.
Infection and Immunity, 67: 675, 1999